EGFR and neoplasm: For example, osimertinib, an SMI known as an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) demonstrates the potential to induce ICD in non-small cell lung cancer (NSCLC) tumor cells through the exposure and release of CRT (Furukawa et al., 2021).